TickerTalks
Browse all tickers →
TickerTalks›$IOVA
IOIOVA

Iovance Biotherapeutics, Inc.

$IOVA·$2.8B·Biotechnology·Healthcare
$8.79+1.0%YTD+56.8%1Y+299.5%
Mentions · last 7 days
2026-08-29: 14 posts2026-08-30: 23 posts2026-08-31: 40 posts2026-09-01: 28 posts2026-09-02: 66 posts2026-09-03: 43 posts2026-09-04: 56 posts270+36%
Price updated 4h ago·X counts updated 2h ago
IOIOVA
$IOVAIovance Biotherapeutics, Inc.
$8.79+1.03%270 posts+36%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $IOVA, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersAcceleratingAI verdict · as of 2026-09-04

The move is getting stronger, with heavier trading behind it.

Iovance's Amtagvi TIL therapy is ramping fast, the company partnered with Texas Oncology to enter community settings, and the UAE is reportedly circling — the launch is on.

Iovance Biotherapeutics makes Amtagvi, the first tumor-infiltrating lymphocyte (TIL) cell therapy approved for advanced melanoma. The equity has been a genuine turnaround as commercial adoption and hiring both accelerated.

  • The commercial ramp is landing: Q1 revenue was $71.4M, up 45% YoY, following +18%, +15%, +93% in the prior quarters — the trajectory is real acceleration, and gross margin near 98% shows Amtagvi is being sold at expected commercial economics rather than heavy launch subsidies.
  • The Texas Oncology partnership matters: extending TIL therapy into community oncology — where most cancer patients are actually treated — is a real expansion of the addressable patient pool beyond the academic centers where cell therapies traditionally launch; management hired 64 new employees over June-August in a coordinated ramp for Q3-Q4 execution, which lines up with the volume pipeline.
  • M&A optionality is visible: TD Cowen listed IOVA on its biotech acquisition target list, and the UAE reportedly met with Iovance last week as a potential M&A harbinger — combined with position at 91% of the 52-week range and +123% above the 200-day, the setup is a compounder that's re-rated but with real strategic optionality still on the table.

November 5 Q3 earnings is the near-term confirmation — a Q3 print with revenue above $90M and continued gross margin above 95% validates the launch trajectory. A launch-slowdown surprise or a payer-mix compression resets the setup; watch community-oncology infusion cadence and any M&A-related 8-K.

Agrees with X sentimentI agree with the bull framing — the 45% Q1 revenue growth, Texas Oncology partnership extending TIL into community settings, 64 new hires June-August, TD Cowen's acquisition-target list, and the UAE meeting are all real and coherent; this is exactly what a well-executed cell-therapy launch looks like.

What to watch: November 5 Q3 earnings — revenue above $90M with gross margin above 95% validates the launch trajectory. A launch-slowdown surprise or payer-mix compression resets the setup; watch community-oncology infusion cadence and any M&A 8-K.

On the calendar: 2026-11-05 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment85 posts analyzed · as of 2026-09-04

$IOVA (Iovance) chatter is aggressively bullish. Bulls call out that no analyst has included the infrastructure being built ahead of NSCLC in their valuations, the company is on the M&A shortlist with a clean balance sheet and no debt, and Interim CEO Fred Vogt says investors will 'wake up to positive and persuasive news.' Cellular immunotherapy is called an era-defining bet, and IOV-5001's basket trial targeting colorectal cancer stands out. Recent hiring spree suggests scaling ahead of NSCLC launch. The tone is 'a monster being built to be lean, smart, efficient and PROFITABLE.' Very little bearish counter.

Read the AI verdict + X sentiment for $IOVA

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops tumor-infiltrating lymphocyte cell therapies for solid tumors, with Amtagvi approved for advanced melanoma.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $IOVA.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $IOVA

Neutral — binary clinical-stage catalyst set is independent of the broader industry macro driver; pipeline readout timing is the company-specific event.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+51.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-4.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-45.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-127%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-20.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
5.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-50.2%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
115%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.11$-0.13+17.6%
Q1 2026May 7, 2026$-0.19$-0.190.0%
Q4 2025Feb 24, 2026$-0.18$-0.22+18.2%
Q3 2025Nov 6, 2025$-0.25$-0.29+13.8%
Next earningsThu, Nov 5·consensus EPS $-0.12

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$71.4M+44.8%98.6%-113%$-0.19$-78.7M
Q4 FY25$86.8M+17.7%216%-84.7%$-0.15$-61.9M
Q3 FY25$67.5M+15.2%97.9%-141%$-0.25$-89.5M
Q2 FY25$60.0M+92.7%5.5%-190%$-0.33$-74.9M

Forward consensus

5-year forecast · up to 7 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$362.2M$355.0M – $371.5M-$0.56-$0.67 – -$0.377
FY27$496.5M$482.8M – $511.0M-$0.31-$0.40 – -$0.266
FY28$741.2M$569.5M – $1.1B$0.00-$0.20 – $0.226
FY29$987.2M$895.7M – $1.1B$0.21$0.19 – $0.265
FY30$1.2B$1.1B – $1.4B$0.43$0.38 – $0.513

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.91%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+49.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+123.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 387.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today3.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.705-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 39 other (14 exempts · 14 inkinds · 11 awards) in window

See when $IOVA insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

S-3ASRAuto-shelf registrationJun 18S-3ASR
AI summary

Iovance Biotherapeutics (IOVA) filed an automatic shelf registration statement (Form S-3ASR) on June 18, 2026, effective immediately upon filing under Rule 462(e) as a well-known seasoned issuer. Interim CEO Frederick G. Vogt signed the filing; the company is headquartered in San Carlos, CA. The shelf enables future securities offerings at Iovance's discretion; no specific offering amount or timing was disclosed.

8-KShareholder voteJun 108-K — Item 5.07: Shareholder vote · Item 8.01: Other event
AI summary

Iovance Biotherapeutics held its 2026 Annual Meeting on June 10, 2026, with ~74% of shares represented. Stockholders voted on seven proposals including election of six directors, advisory say-on-pay, frequency of future say-on-pay votes, ratification of Ernst & Young LLP as auditor, a 1,000,000-share ESPP increase, and an increase to authorized shares of common stock (the exact count and results are in the attachments). The authorized share increase is mildly dilutive optionality; remaining items are routine governance.

8-KOfficer or director changeMar 208-K — Item 5.02: Officer or director change
AI summary

IOVA disclosed a personnel change (8-K Item 5.02, dated 2026-03-20). An executive departure and a new appointment are both reported. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

+ 16 other (4 13Gs · 2 routine 8-Ks · 2 10-Qs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Oncology Stocks to Add to Your Portfolio as Cancer Care Evolveszacks.com·9d agoZacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigenzacks.com·9d ago5 Biotech Stocks Worth Adding to Your Portfolio Nowzacks.com·10d agoIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)globenewswire.com·14d agoIovance Biotherapeutics Stock Is Trending Friday: What's Going On?benzinga.com·15d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$AURA$MRNA$ALT$NWBO$SLS$RARE$IBRX$ABCL
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport